Carolina Urologic Research Center, Myrtle Beach, SC, USA.
Future Oncol. 2022 Jul;18(21):2575-2584. doi: 10.2217/fon-2022-0172. Epub 2022 May 19.
WHAT IS THIS SUMMARY ABOUT?: This is a summary of a research study (known as a clinical trial) called HERO. The HERO study compared how well relugolix and leuprolide worked in lowering blood testosterone to sustained castration levels in men with advanced prostate cancer. Sustained castration is a blood testosterone level below 50 ng/dl from Day 29 through 48 weeks of treatment.
WHAT WERE THE RESULTS?: Researchers looked at 930 adult men with advanced prostate cancer: 622 of these men took relugolix (by mouth once daily) and 308 received leuprolide (injected every 3 months). The HERO study showed that more men taking relugolix (97%) achieved sustained castration through 48 weeks than men receiving leuprolide (89%). This decrease in testosterone also happened more quickly in men taking relugolix. In 184 men who were followed up for 90 days after completing treatment, blood levels of testosterone returned to normal in more men who took relugolix than men who received leuprolide. Side effects were similar among men taking relugolix or receiving leuprolide, and most were identified as mild or moderate in terms of how bad they were.
WHAT DO THE RESULTS OF THE STUDY MEAN?: In men with advanced prostate cancer and compared with those receiving leuprolide, more men taking relugolix had lower levels of blood testosterone. ClinicalTrials.gov NCT number: NCT03085095.
这是一项名为 HERO 的研究的总结。该研究比较了瑞戈非尼（relugolix）和亮丙瑞林（leuprolide）在降低晚期前列腺癌男性的血液睾酮至持续去势水平方面的效果。持续去势是指从第 29 天到治疗 48 周时，血液睾酮水平低于 50ng/dl。
研究人员观察了 930 名患有晚期前列腺癌的成年男性：其中 622 名男性服用瑞戈非尼（每日一次口服），308 名接受亮丙瑞林（每 3 个月注射一次）。HERO 研究表明，接受瑞戈非尼治疗的男性中有 97%（622 人中有 610 人）在 48 周时达到持续去势，而接受亮丙瑞林治疗的男性中这一比例为 89%（308 人中有 276 人）。服用瑞戈非尼的男性中睾酮的下降也更快。在完成治疗后随访 90 天的 184 名男性中，服用瑞戈非尼的男性中血液睾酮水平恢复正常的人数多于接受亮丙瑞林治疗的男性。服用瑞戈非尼或接受亮丙瑞林的男性的副作用相似，大多数被认为是轻度或中度的。
在晚期前列腺癌男性中，与接受亮丙瑞林治疗的男性相比，更多服用瑞戈非尼的男性血液中的睾酮水平更低。ClinicalTrials.gov NCT number: NCT03085095。
